

Date and Time: *Tuesday 16 August 2016, 10:00-16:30*

Minutes: Confirmed

ADHD Guideline Committee (GC) Meeting 4

Place: *Rosenheim and Pickering Room, 180 Great Portland Street, London W1W 5QZ*

Present:

Gillian Baird (GB)	Professor of Paediatric Neurodisability and Consultant Developmental Paediatrician, Chair
Emily Simonoff (ES)	Professor of Child & Adolescent Psychiatry, Clinical Specialist
Philip Asherson (PA)	Professor of Psychiatry and Honorary Consultant Psychiatrist
Poppy Ellis Logan (PEL)	Lay Member
Jean Fitzpatrick (JF)	Lay Member
Gisli Gudjonsson (GG)	Professor of Psychology
Nicole Horwitz (NH)	Consultant Community Paediatrician
Jen Lewis-Neill (JLN)	Clinical Lead/Independent Nurse prescriber
Karen Pratt (KP)	Paediatric Nurse Specialist for Neurodisability
Jonathan Rackham (JR)	Lay Member
Kapil Sayal (KS)	Professor of Child & Adolescent Psychiatry and Honorary Consultant Psychiatrist
David Traxson (DT)	Educational Psychologist
Jody Warner-Rogers (JWR)	Consultant Clinical Psychologist and Paediatric Neuropsychologist
Ian Wong (IW)	Professor of Pharmacy Practice and Medicine Evaluation

NGC technical team

Toluwa Akindele-Ajani (TA)	Research Fellow
Joanna Ashe (JA) (Item 6 only)	Senior Information Specialist,
Katie Broomfield (KB)	Document Editor/Process Assistant (notes)
Caroline Farmer (CF)	Senior Research Fellow
Elisabetta Fenu (EF)	Health Economics Lead
Samantha Jones (SJ) (Items 1-3 only)	Project Manager
Kate Kelley (KK)	Guideline Lead

Apologies

Marios Adamou (MA)	Consultant Psychiatrist (adults) and Visiting Professor
Alex Allen (AA)	Senior Research Fellow
Rebecca Boffa (RB)	Research Fellow
Polly Branney (PB)	General Practitioner
Margaret Constanti (MC)	Senior Health Economist
Chris Hollis (CH)	Professor of Child & Adolescent Psychiatry and Consultant in Developmental Neuropsychiatry

Notes

1. The Chair welcomed the group to the fourth meeting of this GC and introductions were made. Apologies were received from MA, AA, RB, PB, MC, CH.
2. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to previous declarations recorded in the DOI register, for this meeting, no action applies. The following new declarations of interest were received for this GC meeting:

GC Declarations of Interest			
N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
JF	I am speaking at the annual ADHD Conference at Liverpool on the 13th and 14th of October 2016.	Personal non-financial non-specific	Declare and participate
JWR	<p>I have been asked to become involved in an e-learning programme project with MindEd, an organisation that provides free mental health learning materials for professionals and the general public. MindEd has been commissioned by Health Education England (HEE), to develop on-line courses on several topics relevant to child and adolescent mental health. These courses will be designed to support components of the Children and Young People Improved Access to Psychological Therapies (CYP-IAPT).</p> <p>The chapter I am involved in with ADHD does not recommend any specific treatment or commercial packages for assessment/management and will not be outlining any specific intervention approach, though other areas within the wider e-learning package may do so.</p> <p>There is a small honorarium for contributing – I am unsure at this stage of exact amount.</p>	Personal financial non-specific	Declare and participate
NICE DOI policy classifications are:			
<ul style="list-style-type: none"> • Personal financial specific 			

- Personal financial non-specific
- Personal non-financial specific
- Personal non-financial non-specific
- Non-personal financial specific
- Non-personal financial non-specific

3. The minutes and notes from GC3 were reviewed. They were agreed to be an accurate record of the meeting.
4. The GC discussed the evidence for the pharmacological treatment review.
5. CF gave a presentation on the clinical evidence for the sequencing of pharmacological treatment review. EF gave a presentation on the health economic evidence for this review. The group discussed the evidence.
6. CF gave a presentation on the clinical evidence for the withdrawal of pharmacological treatment review. There was no health economic evidence for this review question. The group discussed the evidence.
7. The group discussed protocols for Q2 & Q4 (post-diagnostic advice), Q3 & Q5 (methods of providing post-diagnostic advice) and Q1 (high risk groups).
8. AOB: the group discussed next steps and agreed action points.

Date, time and venue of the next meeting

GC5: Friday 07 October 2016, Boardroom, National Guideline Centre